Novartis AG (NVS)
| Market Cap | 204.76B |
| Revenue (ttm) | 51.56B |
| Net Income (ttm) | 8.98B |
| Shares Out | 2.24B |
| EPS (ttm) | 3.95 |
| PE Ratio | 21.17 |
| Forward PE | 12.27 |
| Dividend | $3.20 (3.83%) |
| Ex-Dividend Date | Mar 4, 2021 |
| Volume | 1,850,844 |
| Open | 83.56 |
| Previous Close | 82.80 |
| Day's Range | 83.53 - 83.98 |
| 52-Week Range | 74.07 - 95.17 |
| Beta | 0.52 |
| Analysts | Strong Buy |
| Price Target | 104.50 (+25.0%) |
| Est. Earnings Date | Oct 26, 2021 |
About NVS
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to...
Financial Performance
In 2020, Novartis's revenue was $49.90 billion, an increase of 2.51% compared to the previous year's $48.68 billion. Earnings were $8.07 billion, a decrease of -31.20%.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for Novartis stock is "Strong Buy." The 12-month stock price forecast is 104.50, which is an increase of 25.04% from the latest price.
News
Novartis Adds Vision Loss Gene Therapy Program Via Arctos Acquisition
Novartis AG (NYSE: NVS) has acquired Arctos Medical, adding a preclinical optogenetics-based AAV gene therapy program and Arctos' proprietary technology to its ophthalmology portfolio. Deal terms were ...
Novartis buys gene therapy company Arctos Medical
Novartis has bought gene therapy specialist Arctos Medical to boost its efforts finding treatments for patients with severe vision loss, the Swiss company said on Tuesday.
Why Did Deutsche Bank Downgrade This Big Pharma Stock?
Deutsche Bank has downgraded Novartis AG (NYSE: NVS) to Sell from Hold with a price target of CHF 70, down from CHF 80. Analyst Emmanuel Papadakis sees "grounds for outright caution near term" with Opt...
Novartis' Kisqali Combo Therapy Extends Survival By One Year In Breast Cancer Patients
Novartis AG (NYSE: NVS) announced results of the final overall survival (OS) analysis of Phase 3 MONALEESA-2 study, which evaluated Kisqali (ribociclib) in combination with letrozole in breast cancer pa...
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breas...
EAST HANOVER, N.J., Sept. 19, 2021 /PRNewswire/ -- Novartis today announced results of the final overall survival (OS) analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali ® (ribociclib)...
Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA...
Basel, September 17, 2021— Novartis today announced important findings from a real-world study evaluating the safety and efficacy of alpelisib for people living with PIK3CA-Related Overgrowth Spectrum (...
Novartis' Prostate Cancer Therapy Linked To Improved Quality Of Life
Novartis AG (NYSE: NVS) is building the case for its radioligand therapy, 177Lu-PSMA-617. With positive Phase 3 primary endpoint data in the bag, Novartis at the European Society of Medical Oncology Con...
Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with...
Basel, September 17, 2021 — Novartis today announced positive health-related quality of life (HRQoL) data from its Phase III VISION study evaluating 177Lu-PSMA-617, an investigational targeted radioliga...
3 International Stocks to Buy for Dividend Growth
International stocks tend to offer higher yields than their U.S.-based counterparts, and also offer geographic diversification. The post 3 International Stocks to Buy for Dividend Growth appeared first ...
Novartis Stops Iscalimab Trial In Kidney Transplant Patients
Novartis AG (NYSE: NVS) has halted a Phase 2 trial of CFZ533 (iscalimab) in kidney transplant patients. The decision follows interim data that showed iscalimab was not as good as tacrolimus-based treatm...
Novartis, NHS England Ink Access Deal For Cholesterol Drug Leqvio
The U.K. government, NHS England, and Novartis AG (NYSE: NVS) unveiled a "world-first" reimbursement deal for providing broader access to anti-cholesterol drug Leqvio (inclisiran) after the U.K.'s healt...
World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lower...
Basel, September 01, 2021 — Novartis has reached a commercial agreement with the NHS in England as part of a collaboration to pioneer a first-of-its-kind population health management approach to address...
Novartis presents important overall survival and quality-of-life results across solid tumor portfolio, among other ke...
Basel, August 30, 2021 — Novartis will present new data from its robust portfolio and pipeline of advanced therapeutic platforms in solid tumors, with more than 55 abstracts from Novartis-sponsored and ...
Tonight! Novartis, Roche, BeiGene, Others Discuss Global Fight Against Cancer In Covid Era
Against that backdrop, Forbes China will hold the second “Forbes China Healthcare Summit” at 8pm ET tonight (8am on August 28 in China).
Lonza appoints Novartis executive as new Chief Financial Officer
Lonza has appointed former Novartis executive Philippe Deecke as its new Chief Financial Officer, the Swiss chemicals company said on Thursday.
Novartis' STAMP Inhibitor Under FDA Review For Myeloid Leukemia
The FDA has accepted for review Novartis AG's (NYSE: NVS) marketing application seeking approval for asciminib (ABL001) in chronic myeloid leukemia (CML). Under Priority Review, the application is based...
Novartis (NVS) Kymriah Misses Primary Endpoint in NHL Study
Novartis' (NVS) phase III study evaluating Kymriah for second-line treatment of patients with aggressive B-cell NHL fails to achieve primary endpoint of the study.
Novartis's Kymriah Flunks In Late-Stage NHL Study
Novartis AG's (NYSE: NVS) Kymriah (tisagenlecleucel) CAR-T therapy failed to meet its primary endpoint of event-free survival in a Phase 3 study in aggressive B-cell non-Hodgkin lymphoma (NHL). The BELI...
Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Ho...
Basel, August 24, 2021 — Novartis today announced an update on the Phase III BELINDA study investigating Kymriah® (tisagenlecleucel) in aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack...
FDA, MSK, Novartis, Kevin Rudd To Discuss Int'l Collaboration To Fight Cancer On Aug. 27
Free event will be held online
Novartis Shares Two Year Beovu Data From Diabetic Macular Edema Studies
Novartis AG (NYSE: NVS) has reported data from two Phase 3 trials assessing Beovu (brolucizumab) 6 mg versus Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Eylea (aflibercept) 2 mg in patients with diab...
Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathe...
Ad hoc announcement pursuant to Art. 53 LR